This study is being conducted to quantify the clinical safety and efficacy of head and neck cooling when applied up to 8 days after mild traumatic brain injury (mTBI) among adolescents participating in sporting activities.
This is a single-center, prospective, randomized, non-blinded, dual-arm comparator study that will include two-phases, the 60-patient pilot study (30 patients in the treatment arm and 30 patients in the control arm) followed by a pivotal study (up to 200 patients in the treatment and control arm combined) for a total of up to 260 patients overall in both phases. The pilot study will serve as an opportunity to assess the protocol and make adjustments, if necessary. In addition, descriptive statistics including effect size will be calculated and the safety of the device will be assessed at the conclusion of the pilot study. Subjects will be assigned to study arm based on a block randomization schedule generated a priori. The study sponsor believes that the device and therapeutic treatment that will be evaluated in this study is a non-significant risk (NSR) to the subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
174
A non-invasive hypothermic therapy ("cold therapy") TecTraum device that provides localized cooling of the head and neck.
University of Michigan - Michigan Medicine
Ann Arbor, Michigan, United States
Akron Children's Hospital
Akron, Ohio, United States
Akron Children's Hospital, Mahoning Valley Campus
Boardman, Ohio, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
The SCAT5 overall score will be collected at the initial visit in the Sports Medicine Clinic, and compared to follow-up visits throughout the study, with the objective of demonstrating better outcomes in the treatment group compared to the control group.
Formal statistical hypothesis testing will be employed in the evaluation of this endpoint. Additionally, comparisons between treatment groups on the baseline SCAT5 (SCAT5-PRE) will be performed at initial visit (as reported by subject) and at each follow-up (72 hours, 10 days, and 4 weeks) separately to evaluate the time trend in recovery. Individual SCAT5 symptoms, each scored on a scale of 0-6, will also be summarized and compared by treatment group to investigate the effect of treatment on specific symptoms. These comparisons are intended to provide additional information on the pattern of recovery and are not attached to intended labeling claims; however, statistical testing of these endpoints will be accompanied by adjustment for multiplicity using the Hochberg-Holm method.
Time frame: Change from initial visit to 4 weeks
Recovery time from initial visit, summarized by group and compared in the treatment group to control.
Recovery time from initial visit will be formally evaluated for differences between treatment and control.
Time frame: Initial visit through earliest follow up where complete recovery is observed, maximum of 4 weeks after initial visit.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dayton Children's Hospital
Dayton, Ohio, United States